LongLife Bio-Pharmaceutical
LongLife Bio-Pharmaceutical, also known as CQLongLife, is a prominent player in the biopharmaceutical industry, headquartered in China (CN). Founded in 2001, the company has established itself as a leader in the development and production of innovative biopharmaceutical products, focusing on areas such as oncology, immunology, and infectious diseases. With a commitment to quality and research, LongLife Bio-Pharmaceutical offers a range of unique therapies that leverage advanced biotechnology. The company has achieved significant milestones, including numerous regulatory approvals and partnerships that enhance its market position. Recognised for its dedication to improving patient outcomes, LongLife continues to expand its operational reach across major regions in Asia and beyond, solidifying its reputation as a trusted name in the biopharmaceutical sector.
DitchCarbon Score
How does LongLife Bio-Pharmaceutical's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
LongLife Bio-Pharmaceutical's score of 0 is lower than 78% of the industry. This can give you a sense of how well the company is doing compared to its peers.
LongLife Bio-Pharmaceutical's reported carbon emissions
LongLife Bio-Pharmaceutical, headquartered in CN, currently does not have available carbon emissions data for the most recent year, nor does it provide specific reduction targets or initiatives. Without concrete figures or commitments, it is challenging to assess their climate impact or sustainability efforts. The company may be in the process of developing its climate strategy or reporting framework, which is common in the bio-pharmaceutical industry as organisations increasingly focus on reducing their carbon footprint and enhancing environmental responsibility.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
LongLife Bio-Pharmaceutical is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
